Proposed Study of CLL Samples
- To analyze the expression of a variety of informative molecules using a unique
high-resolution flow cytometric immunophenotyping technology in samples from patients
with chronic lymphocytic leukemia enrolled in clinical trial ECOG-2997.
OUTLINE: Cell samples are analyzed for the following prognostic biomarkers: ZAP-70,
phospho-Syk, phospho-GSK-3β, phospho-Akt, phospho-ZAP-70, cyclin D1, cyclin D2, p21cip1,
phospho-ReIA, IkappaBα, Bax, Mcl-1, PTEN, phospho-Erk1/2, and phospho-MEK1/2. Biomarker
signals are amplified using enzymatic amplification staining to obtain high resolution
detection of cell-surface markers on leukemic cells. Biomarker expression levels are
measured using fluorescence activated cell sorting analysis. Relationships between clinical
outcomes, standard flow cytometric analysis, cytogenetic studies, and high resolution
immunophenotyping will also be assessed.
Correlation of biomarker analysis with complete response
David Kaplan, MD, PhD
University Hospitals Seidman Cancer Center